MedTrace Logo

Assessment of the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate Osteoarthritis

NCT03262792 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2021-07-15

No results posted yet for this study

Summary

This is a 12 weeks randomized, double-blind, placebo-controlled clinical study to assess the effect of Andrographis Paniculata at low dose of 300 mg/day and high dose of 600 mg/day in the study population in the age range of 40-70 years and suffering from mild-moderate OA.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

Microcrystalline cellulose

DIETARY_SUPPLEMENT

Andrographis Paniculata

Andrographis Paniculata 150 mg

DIETARY_SUPPLEMENT

Andrographis Paniculata

Andrographis Paniculata 300 mg

Sponsors & Collaborators

  • Vedic Lifesciences Pvt. Ltd.

    lead INDUSTRY

Principal Investigators

  • Shalini Srivastava, MD · Vedic Lifesciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-13
Primary Completion
2018-07-30
Completion
2018-08-27

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03262792 on ClinicalTrials.gov